
Visa Survey: Physical Gifts Lead Holiday Spend Despite Travel Demand
A new Visa survey indicates consumers are prioritizing tangible merchandise for holiday budgets even as travel and experiences top seasonal wish lists.
Global supply chains, trade corridors, corporate earnings, and monetary policy.

A new Visa survey indicates consumers are prioritizing tangible merchandise for holiday budgets even as travel and experiences top seasonal wish lists.

Expedia CEO Ariane Gorin tells CNBC that while autonomous AI agents mark an exciting era for travel, consumer booking habits remain unchanged for now.

The fast-food operator declined the $1.4 billion buyout proposal, asserting the offer undervalues potential gains from its ongoing turnaround strategy.

Food technology venture Wonder initiates a confidential public offering process, testing equity market appetite for consumer logistics.

Moderna raises its full-year 2026 revenue growth guidance to between 15% and 25%, citing accelerating commercial traction across its newer vaccine portfolio.

Tesla plans to phase out Cybertruck manufacturing in Texas next year to reallocate capacity toward its autonomous Cybercab program, following niche sales.

Surging fuel prices drive up holiday freight rates, forcing small and midsize merchants to navigate severe cost pressures during peak retail demand.

Rising commodity, logistics, and semiconductor memory expenses collide with weakening consumer pricing power across the global automotive sector.

Experiential venue operator Cosm is scaling its immersive screening library, capitalizing on consumer demand for high-margin theatrical formats.

Market analysis from MarketWatch highlights how heavy artificial intelligence weighting undermines traditional diversification within the benchmark S&P 500.

Federal income-tax thresholds and standard deductions will climb at a faster pace for 2027, reflecting persistent inflation pressures across the U.S. economy.

MarketWatch reports that Medicare beneficiaries face a projected 50% spike in prescription drug expenses for 2027, making open enrollment reviews essential.